The Classic Myeloproliferative Neoplasms

Implementing a Utilization Approach

October 2011

I want to conclude by bringing up what I think are 5 important points in trying to implement a utilization approach for the MPNs in the laboratory. Most importantly, there needs to be effective communication between the clinician, pathologist, and laboratory. This is essential if any kind of utilization screening is to work. It is also necessary to obtain pertinent information, CBC, erythropoietin, morphologic findings, JAK2 V617F, etc, so a sequential evaluation can occur. One needs to use a consistent and standard process. For example, following a mutually agreed upon algorithm. It’s appropriate and necessary to use your reports to communicate your process, decisions, and findings, and finally, auditing your results is necessary to assure that the process is giving you and your clinical colleague the desired outcome.

< Previous Slide

Implementing a Utilization Approach

Next Slide >

 

Jump to section:

• Introduction
• Optimizing Laboratory Testing for Hematologic Disorders Series
• Goals for Today's Presentation
• Example of a Recent MPN Referral
• Why Do We Have Test Utilization Issues?
• Why Do We Have Test Utilization Issues?
• So What Should We Do?
• WHO Classification
• Important Laboratory Assays in the MPNs
• JAK2 V617F Background
• JAK2 V617F Background
• Question #1 — JAK2 V617F
• JAK2 V617F
• JAK2 V617F at Mayo Clinic
• Conclusion #1 — JAK2 V617F
• JAK2 Exon 12 Sequencing Background
• Question #2 — JAK2 Exon 12 Sequencing
• JAK2 Exon 12 Sequencing: When Not to Use
• JAK2 Exon 12 Sequencing
• Conclusion #2 — JAK2 Exon 12 Sequencing
• MPL Exon 10 Sequencing Studies: Background
• Question #3 — MPL Exon 10 Sequencing
• MPL Exon 10 Sequencing: When to Use
• MPL Exon 10 Sequencing: When Not to Use
• MPL Exon 10 Sequencing
• Conclusion #3 — MPL Exon 10 Sequencing
• Roles of Other Assays in Classic MPN
• Summary
• Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
• Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
• Implementing a Utilization Approach
• Questions